Amphastar Pharmaceuticals (AMPH) Other Non-Current Liabilities (2014 - 2026)

Amphastar Pharmaceuticals has reported Other Non-Current Liabilities for 13 years, with the latest figure at $29.4 million in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 5.93% year-over-year to $29.4 million in Q2 2026; TTM through Jun 2026 was $29.4 million, a 5.93% increase from a year earlier, with the FY2025 full-year figure at $30.0 million, up 43.13% from the prior year.
• Other Non-Current Liabilities was $29.4 million for Q2 2026 at Amphastar Pharmaceuticals, roughly flat from $29.4 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $30.0 million in Q4 2025, with the low at $14.2 million in Q3 2022.
• Average Other Non-Current Liabilities over 5 years is $21.4 million, with a median of $19.9 million recorded in 2024.
• The largest YoY upside for Other Non-Current Liabilities was 72.22% in 2024 against a maximum downside of 7.8% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $14.6 million in 2022, then soared by 55.98% to $22.7 million in 2023, then decreased by 7.8% to $20.9 million in 2024, then surged by 43.13% to $30.0 million in 2025, then retreated by 1.78% to $29.4 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $29.4 million (Q2 2026), $29.4 million (Q1 2026), and $30.0 million (Q4 2025), per Business Quant data.